Name: | Description: | Size: | Format: | |
---|---|---|---|---|
2.96 MB | Adobe PDF |
Advisor(s)
Abstract(s)
ASAS and EULAR recommend the use of an improvement ≥1.1 in ASDAS at 12 weeks to determine the continuation of a bDMARD. However, it is debated whether improvements can occur and whether patients’ characteristics influence (time to) response.
Description
Fourteenth International Congress on Spondyloarthritides
Keywords
Citation
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism